Atara Biotherapeutics Inc

NASDAQ:ATRA  
12.05
-0.31 (-2.51%)
7:39:51 PM EDT: $12.60 +0.55 (+4.56%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)82.50M
Current PE14.24
Forward PE 5.17
2yr Forward PE 133.89
See more stats
Estimates Current Quarter
Revenue$3.73 Million
Adjusted EPS-$0.67
See more estimates
10-Day MA$12.08
50-Day MA$10.53
200-Day MA$9.32
See more pivots

Atara Biotherapeutics Inc Stock, NASDAQ:ATRA

1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, California 91320
United States of America
Phone: +1.805.623.4211
Number of Employees: 153

Description

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.